Signet Ring Cell Carcinoma of the Appendix: What It Means and How It Is Treated
Signet ring cell carcinoma of the appendix is a high-grade form of appendiceal adenocarcinoma. Its cells are so full of mucus that the nucleus is pushed to one side, like a signet ring. The 2025 consensus guidelines from the Peritoneal Surface Malignancy (PSM) Consortium treat signet ring cells as a high-risk feature. That means a right hemicolectomy, chemotherapy considered after surgery even without lymph node spread, chemotherapy before cytoreductive surgery if the cancer has reached the abdomen, and closer follow-up.
Signet ring cell carcinoma is often the hardest appendix cancer diagnosis to hear. The words high grade and signet ring cells usually come together on the report, and families quickly find out that this is one of the more aggressive forms of appendix cancer. We built this page to explain what the diagnosis means, what the 2025 guidelines recommend, and where the evidence is still thin.
Signet ring cell carcinoma is part of the larger appendiceal adenocarcinoma group, and most of the same guideline pathway applies. This page focuses on what is different when signet ring cells are present. Dr. Michael Foote, who reviewed this page, is one of the authors of the 2025 guidelines. Sources are listed at the bottom.
What signet ring cell carcinoma is
Signet ring cells are cancer cells packed with mucus. The mucus pushes the cell’s nucleus against one edge, so under the microscope the cell looks like a ring with a signet stone. These cells tend to spread through tissue as single cells or small groups rather than forming glands, which is part of why they behave aggressively.
Under World Health Organization (WHO) criteria, a tumor is called signet ring cell carcinoma when signet ring cells make up more than half of it. When there are fewer, the report usually says something like mucinous adenocarcinoma with signet ring cells. Either way, the 2025 guidelines treat the presence of signet ring cells as important. They place it in grade 3, the highest grade, and list it among the high-risk features that change treatment.
Signet ring cells and other appendix cancers
- Goblet cell adenocarcinoma. Higher-grade goblet cell adenocarcinoma can contain signet ring-like cells. An older Tang category was even called adenocarcinoma ex-goblet cell carcinoid, signet ring cell type. If your report mentions goblet cells, that page applies to you.
- PMP grade 3. When mucinous disease spreads in the abdomen, the 2025 guidelines grade it 1 to 3. Grade 3, the highest, is reserved for disease with signet ring cells. The grade in the abdomen can differ from the grade in the appendix, so ask whether signet ring cells were seen in each place. Our post on why your appendix and your PMP can have different grades explains this.
- A different starting point. Signet ring cell cancers also start in the stomach, colon, and breast. Pathologists use the appearance of the tumor and special stains to confirm the appendix is the true source. This is one reason the guidelines recommend expert pathology review.
Tests after a signet ring cell carcinoma diagnosis
The 2025 guidelines recommend the same workup as other appendiceal adenocarcinomas: a history and physical exam, CEA, CA-125, and CA 19-9 blood tests with CRP considered, CT or MRI imaging, a colonoscopy, expert pathology review, and discussion at a multidisciplinary tumor board. Two points matter more with signet ring cells:
- Comprehensive tumor profiling (genomic testing of the tumor) should be considered to look for possible drug targets.
- Circulating tumor DNA (ctDNA) blood testing may be considered particularly for high-grade or signet ring cell disease, because it can help with prognosis. The guidelines note that evidence for ctDNA in appendix cancer is still limited.
Treatment for signet ring cell carcinoma under the 2025 guidelines
When the cancer has not spread to the abdomen
The guidelines recommend a right hemicolectomy, which removes the right side of the colon and its lymph nodes, aiming for at least 12 nodes. Because signet ring cells are a confirmed high-risk feature in appendix cancer, chemotherapy after surgery should be considered for stage III disease and for stage II disease with signet ring cells. Usual options are FOLFOX, or a stronger three-drug regimen such as FOLFOXIRI or FOLFIRINOX, which causes more side effects, typically for 3 to 6 months with a goal of 6.
Signet ring tumors spread to lymph nodes more often than low-grade tumors. A 2026 study of 205 patients at a UK peritoneal center found cancer in the lymph nodes in about a third of signet ring cell tumors, compared with about 1 percent of well differentiated mucinous adenocarcinomas.
When signet ring cell carcinoma has spread to the abdomen
Disease with signet ring cells in the abdomen is grade 3. For grade 2 or 3 disease, the guidelines recommend both cytoreductive surgery (CRS) and chemotherapy through the vein. Most experts prefer to give chemotherapy first, check the response, and then plan surgery. CRS removes all visible tumor in the abdomen and is often paired with heated chemotherapy inside the abdomen (HIPEC). Chemotherapy usually totals about 6 months, finished after surgery if not completed before.
If complete removal still does not look possible after chemotherapy, or the disease grows during treatment, the guidelines advise against CRS as a definitive treatment. Options then include more chemotherapy, clinical trials, and supportive care. Debulking surgery may help some people with symptoms, but it is not curative.
Where experts still disagree
The evidence for chemotherapy timing in signet ring cell disease comes from small studies that look back at past patients, and the results conflict. The guidelines prefer chemotherapy before surgery partly to see how the cancer responds. Some single-center studies, including a 2019 study from Mercy Medical Center in Baltimore, did not find better outcomes with chemotherapy before CRS in high-grade mucinous disease with or without signet ring cells. Patients who get chemotherapy first may also have had more aggressive disease to begin with, which makes these studies hard to interpret. This is a fair topic to raise with both your surgeon and your medical oncologist, and a strong reason to be treated at a center with deep experience in this disease. The medical centers and providers page lists centers that treat appendix cancer often.
Surveillance after signet ring cell carcinoma
Follow-up for signet ring cell carcinoma is on the more intensive side. Each visit includes a history and physical exam, CT or MRI of the chest, abdomen, and pelvis, and a CEA blood test plus any marker that was ever high. The 2025 guidelines recommend:
- No spread to the abdomen: every 3 to 6 months for 2 to 4 years, then once a year until 5 to 10 years.
- After treatment for disease in the abdomen: every 3 months for 2 years, then every 6 months for 2 years, then yearly until 5 to 10 years.
- ctDNA testing can be considered, every 3 months for the first year after treatment of grade 2 or 3 disease in the abdomen.
A second-look laparoscopy may be considered when there is concern about early spread that scans can miss.
Research and clinical trials
Signet ring cell carcinoma of the appendix is rare, so most of what is known comes from small groups of patients mixed in with other appendix cancers. The 2025 guidelines recommend genomic testing of the tumor for anyone whose cancer has spread, and say that clinical trials should be part of the conversation, especially when standard treatment is not working. Our trial finder lists studies open to people with appendix cancer. Pooling pathology and genomic data from many people with signet ring cell disease is one of the clearest ways to speed up answers, and it is why the Appendicure registry exists.
Add your signet ring cell data to the registry
The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular data from people with every appendiceal cancer type, including signet ring cell. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.
Already enrolled? Add new reports or correct your record.
Frequently asked questions about signet ring cell carcinoma
What is signet ring cell carcinoma of the appendix?
It is a high-grade form of appendiceal adenocarcinoma in which signet ring cells, cells so full of mucus that the nucleus is pushed to one side, make up more than half of the tumor. The 2025 guidelines treat signet ring cells as a high-risk feature.
Is signet ring cell carcinoma the same as adenocarcinoma with signet ring cells?
Not exactly. Signet ring cell carcinoma means signet ring cells make up more than half of the tumor. Adenocarcinoma with signet ring cells means there are fewer. The 2025 guidelines treat the presence of signet ring cells as high risk in both cases.
Do I need chemotherapy for signet ring cell carcinoma?
Usually, yes. The 2025 guidelines say chemotherapy after surgery should be considered for stage III disease and for stage II disease with signet ring cells, and recommend chemotherapy, usually before cytoreductive surgery, when the cancer has spread to the abdomen.
Is HIPEC used for signet ring cell carcinoma?
When the cancer has spread to the abdomen and all of it can be removed, the guidelines recommend cytoreductive surgery, often with intraperitoneal chemotherapy such as HIPEC, along with chemotherapy through the vein.
What does PMP grade 3 mean?
PMP grade 3 is the highest grade of mucinous disease in the abdomen, and it is reserved for disease that contains signet ring cells. It is treated with chemotherapy and cytoreductive surgery when complete removal is possible.
How often are scans needed after signet ring cell carcinoma?
The 2025 guidelines recommend scans and blood tests every 3 months for 2 years after treatment of disease in the abdomen, or every 3 to 6 months if the cancer had not spread, with follow-up lasting 5 to 10 years.
Related reading
Sources
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867
- Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025;131(13):e35874. doi.org/10.1002/cncr.35874
- Martin-Roman L, Larby L, Strach MC, et al. Evaluating the need for performing a right hemicolectomy in appendiceal adenocarcinomas. Eur J Surg Oncol. 2026;52(11):112090. doi.org/10.1016/j.ejso.2026.112090
- Munoz-Zuluaga CA, King MC, Ledakis P, et al. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin. Eur J Surg Oncol. 2019;45(9):1598-1606. doi.org/10.1016/j.ejso.2019.05.008
- Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi.org/10.1111/his.13975
Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.
